A carregar cotações...
Previsão
O preço-alvo médio dos analistas é € 13,68 (+129,92%). A mediana é € 13,68 (+129,92%).
| Comprar |
5 |
| Manter |
0 |
| Vender |
0 |
Discussões na comunidade
Ainda não há nenhuma discussão sobre este ativo.
Iniciar discussãoNotícias Ir para o feed de notícias
ImmunityBio stock rises after ANKTIVA approval in the UAE
ImmunityBio shares climbed 7.5% after ANKTIVA was approved in the United Arab Emirates. The approval covers ANKTIVA 0.4 mg in combination with BCG for the treatment of adult patients with BCG-unresponsive, non‑muscle‑invasive bladder cancer and ANKTIVA 1.2 mg with immune checkpoint inhibitors for metastatic non‑small‑cell lung cancer. The approval expands ANKTIVA’s regulatory presence to 34 countries and is based on the QUILT‑3.032 study (in NMIBC: 71% complete response rate in the CIS cohort; 12‑month DFR 58.2% in papillary tumors; 83% cystectomy‑free at 36 months) and QUILT‑3.055 (in checkpoint‑refractory NSCLC: median overall survival 14.6 months). » Mais em de.investing.com
ImmunityBio analysis: ANKTIVA plus BCG significantly more cost-effective than TAR-200 in bladder cancer
A health economic analysis presented in Philadelphia shows that ANKTIVA combined with BCG achieves substantial cost savings over three years compared with TAR-200 for BCG-unresponsive, non–muscle-invasive bladder cancer. Savings per avoided cystectomy were $109,622 in year 1, $151,438 in year 2 and $60,393 in year 3; savings per cystectomy-free month were $9,370, $6,144 and $1,520 in years 1–3, respectively. The study attributed the cost reductions to lower acquisition and administration costs and slightly higher complete response rates (49.6% vs. 45.9%). Investors reacted positively; the stock has returned 272% in the past six months and is trading at $7.74. » Mais em de.investing.com
ImmunityBio obtains exclusive US rights to Tokio-172 BCG
ImmunityBio has signed an exclusive development and supply agreement with Japan BCG Laboratory for the Tokio-172 BCG strain in the U.S. and could become the sole BLA applicant. The decision is based on Phase III SWOG S1602 data showing non-inferiority to TICE BCG (HR 0.82) and an estimated 5-year recurrence-free survival of 64% vs. 58%. Tokio-172 is not yet FDA-approved in the U.S.; ImmunityBio is in discussions with the FDA and research institutions about data use and plans regulatory steps. The company reports strong revenue growth but remains unprofitable, and analysts see further upside potential despite recent share gains. » Mais em de.investing.com
ImmunityBio posts strong Anktiva sales growth and expands global access
ImmunityBio reported accelerating commercial traction for Anktiva with Q4 2025 net product revenue up 700% year‑over‑year and unit volumes rising 750%, driven by broadened physician and patient adoption. The company has expanded Anktiva access to 33 countries across four major regulatory jurisdictions and secured an FDA J‑code to improve reimbursement visibility. ImmunityBio is advancing a multi‑layered immunotherapy platform—Anktiva (IL‑15 superagonist), NaNT allogeneic cell therapy, DNA vaccines and Leonardo manufacturing for off‑the‑shelf NK/CAR‑NK products—that management says could scale into an API‑like personalized immune regimen and materially re‑rate the company if execution continues. Continued commercial momentum and regulatory tailwinds underpin a bullish long‑term thesis for IBRX, albeit with execution risk. » Mais em finance.yahoo.com
ImmunityBio posts 168% y/y product revenue jump as ANKTIVA launch gains traction
ImmunityBio reported preliminary results for the quarter ending March 31, 2026, with product revenue rising 168% year over year to $44.2 million following the commercial launch of ANKTIVA. The company recorded $113 million net product revenue in 2025 (up 700% from 2024) and ended the quarter with $380.9 million in cash and cash equivalents. ANKTIVA has regulatory approval across five jurisdictions covering 34 countries, and ImmunityBio is focused on scaling U.S. commercialization and global expansion to broaden revenue streams. » Mais em finance.yahoo.com
Dividendos históricos Dividendos
Todos os indicadores de dividendos Todos os indicadoresDados financeiros da empresa
| (EUR) | setembro de 2026 | YoY |
|---|---|---|
| Receitas | 43,12 mi | 57,83% |
| Ganho bruto | 41,98 mi | 76,37% |
| Ganho líquido | -162,93 mi | 184,30% |
| EBITDA | -131,24 mi | 330,53% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 6,07 bi |
Número de ações | 1,06 bi |
Máximo/mínimo de 52 semanas | € 11,33 - € 1,78 |
Rentabilidade de dividendos | 1,05% |
Dividendos TTM | € 0,0574 |
Beta | 0,13 |
PER (PE Ratio) | -5,84 |
PEG (PEG Ratio) | 0,05 |
P/VC (PB Ratio) | -5,79 |
P/V (PS Ratio) | 36,48 |
Perfil da empresa
A ImmunityBio, Inc., uma empresa de biotecnologia em fase clínica, desenvolve terapêuticas e vacinas para tratar cancros e doenças infeciosas. Oferece plataformas de imunoterapia e terapia celular, incluindo proteínas de fusão anticorpo-citocina, imunomoduladores sintéticos, tecnologias de vacinas, células NK (natural killer) e sistemas imunitários adaptativos (células T). A empresa desenvolve também agentes terapêuticos que se encontram em ensaios clínicos de Fase II ou III para o tratamento de tumores líquidos e sólidos, incluindo cancros da bexiga, do pâncreas e do pulmão, bem como de agentes patogénicos como o SARS-CoV-2 e o VIH. Tem acordos de colaboração com o National Cancer Institute, o National Institute of Deafness and Communication Disorders e a Amyris, Inc.; e acordos de licenciamento com a CytRx Corporation, a EnGeneIC Pty Limited, a GlobeImmune, Inc., o Infectious Disease Research Institute, a Sanford Health, a Shenzhen Beike Biotechnology Co. Ltd., a Sorrento Therapeutics, Inc. e a Viracta Therapeutics, Inc. A empresa foi fundada em 2014 e tem sede em San Diego, Califórnia.
| Nome | ImmunityBio |
| CEO | Richard Gerald Adcock |
| Sede | San Diego,
ca EUA |
| Site | |
| Setor | Cuidados de saúde |
| Indústria | Biotecnologia |
| Entrada em bolsa | 28/07/2015 |
| Colaboradores | 688 |
Análise aprofundada
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
NASDAQ | IBRX |
Frankfurt | 26CA.F |
Düsseldorf | 26CA.DU |
München | 26CA.MU |